Theratechnologies to Present Long-Term Data on TH1902 in Solid Tumors at 2024 ASCO

Theratechnologies Inc., a notable biopharmaceutical company, has announced the presentation of long-term efficacy, safety, and pharmacokinetic (PK) data on its leading investigational peptide-drug conjugate (PDC) candidate, TH1902, also known as sudocetaxel zendusortide. This presentation will take place at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, held from May 31 to June 4, 2024, in Chicago, Illinois. The focus will be on patients with solid tumors.

The upcoming ASCO poster presentation marks the first dissemination of extended data from Parts 1 and 2 of Theratechnologies' Phase 1 clinical trial. This trial involves sudocetaxel zendusortide, targeting patients with various solid tumors. Previously, preliminary evidence of the drug’s antitumor activity was shared at the 2023 ASCO Annual Meeting. This new analysis will provide further details on the drug's long-term efficacy, safety, and PK, specifically for patients administered a dose of 300 mg/m2 every three weeks. These patients have cancers known for high sortilin (SORT1) expression, including ovarian cancer, endometrial cancer, triple-negative breast cancer (TNBC), and melanoma.

Currently, Part 3 of the Phase 1 trial, which focuses on dose optimization in patients with advanced ovarian cancer, is ongoing. “We have eagerly awaited the updated analysis from Parts 1 and 2 of the Phase 1 trial, as it will provide our first evidence of the long-term effects of sudocetaxel zendusortide in patients with solid tumors,” commented Christian Marsolais, Ph.D., Senior Vice President and Chief Medical Officer at Theratechnologies. He highlighted that the forthcoming data is crucial for evaluating this novel PDC as the trial progresses into Part 3.

Details for the poster presentation are scheduled for June 1, 2024, from 9:00 AM to 12:00 PM CDT. The presenting author will be Dr. Ira Winer from the Karmanos Cancer Institute in Detroit, Michigan. The session will fall under the category "Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology," and the poster will be displayed at Hall A, McCormick Place Congress Center, Chicago.

Sudocetaxel zendusortide, the centerpiece of the presentation, is a pioneering sortilin receptor (SORT1)-targeting PDC. This compound is the first to emerge from Theratechnologies’ broader oncology platform. It employs a cleavable linker to attach a proprietary peptide to docetaxel, a well-known chemotherapeutic agent. The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to sudocetaxel zendusortide for treating all sortilin-positive recurrent advanced solid tumors that are refractory to standard therapies.

Theratechnologies has established the SORT1+ Technology™ platform to develop PDCs targeting SORT1, which is expressed in multiple tumor types. SORT1 functions as a "scavenger" receptor, playing a pivotal role in protein internalization, sorting, and trafficking. The expression of SORT1 is linked with aggressive disease, poor prognosis, and decreased survival. It is estimated that SORT1 is present in 40% to 90% of endometrial, ovarian, colorectal, TNBC, and pancreatic cancers, thus making it an attractive target for anticancer drug development.

Theratechnologies (TSX: TH) (NASDAQ: THTX) remains dedicated to the development and commercialization of innovative therapies addressing unmet medical needs. Further information about Theratechnologies is available on the Company's website.